Evaluation of platelet-rich plasma on infraorbital dark circles by using the FACE-Q scales
DOI:
https://doi.org/10.18203/issn.2455-4529.IntJResDermatol20191001Keywords:
Dark circle, Hyperpigmentation, Infraorbital, Platelet-rich plasmaAbstract
Background: Infraorbital dark circles, also referred to as idiopathic cutaneous hyperchromia of the orbital region, periorbital melanosis, periorbital hyperpigmentation or infraorbital pigmentation, is a common condition frequently observed in dark-skinned patients, but has little data in scientific literature. We aimed to discuss our results of PRP procedure in the treatment of infraorbital dark circles using objective scales based on patient satisfaction and the quality of life.
Methods: Between 2016 and 2017, 9 patients complaining of infraorbital darkness were included who underwent 3 sessions of platelet-rich plasma injection. The outcome was determined by the difference in pre- and post- procedure FACE-Q modules which were designed as patient-reported outcome instrument to evaluate the unique outcomes of patients undergoing facial cosmetic procedures. Surveys conducted were modules of satisfaction with facial appearance, satisfaction with skin, psychological function, social function, aging appearance appraisal and satisfaction with outcome.
Results: All patients were followed up a minimum of 9 months. No major complications were recorded. Only transient ecchymosis and edema were seen in all patients who were improved during follow-up. The patient-reported FACE-Q satisfaction and FACE-Q quality of life pre- and post- procedure results showed statistically significant improvement (<0.05). Overall satisfaction with outcome was 83.33±16.25 (range 63–100).
Conclusions: PRP as a potent source of growth factors, can be seen as a safe, biocompatible, autologous and appropriate treatment modality for the dark eye circles formed in lower eye regions which can increase the quality of patients’ lives in terms of social and psychological function.
References
Sarkar R. Idiopathic cutaneous hyperchromia at the orbital region or periorbital hyperpigmentation. J Cutan Aesthet Surg. 2012;5(3):183-4.
Freitag FM, Cestari TF. What causes dark circles under the eyes? J Cosmet Dermatol. 2007;6(3):211-5.
Park SR, Kim HJ, Park HK, Kim JY, Kim NS, Byun KS, et al. Classification by causes of dark circles and appropriate evaluation method of dark circles. Ski Res Technol. 2016;22(3):276-83.
Nofal E, Elkot R, Nofal A, Eldesoky F, Shehata S, Sami M. Evaluation of carboxytherapy and platelet-rich plasma in treatment of periorbital hyperpigmentation: A comparative clinical trial. J Cosmet Dermatol. 2018;17(6):1000-7.
Mehryan P, Zartab H, Rajabi A, Pazhoohi N, Firooz A. Assessment of efficacy of platelet-rich plasma (PRP) on infraorbital dark circles and crow’s feet wrinkles. J Cosmet Dermatol. 2014;13(1):72-8.
Ahmed NA, Mohammed SS, Fatani MI. Treatment of periorbital dark circles: Comparative study of carboxy therapy vs chemical peeling vs mesotherapy. J Cosmet Dermatol. 2018;1:1-7.
Al-Shami SH. Treatment of periorbital hyperpigmentation using platelet-rich plasma injections. Am J Dermatol Venereol. 2014;3(5):87-94.
Ozer K, Kankaya Y, Çolak Ö. An important and overlooked parameter in platelet rich plasma preparation: The mean platelet volume. J Cosmet Dermatol. 2018.
Atashi F, Jaconi MEE, Pittet-Cuénod B, Modarressi A. Autologous platelet-rich plasma: a biological supplement to enhance adipose-derived mesenchymal stem cell expansion. Tissue Eng Part C Methods. 2015;21(3):253-62.
A revolutionary patient-reported outcome instrument by Memorial Sloan-Kettering Cancer Center:FACE-Q. Available at: http://qportfolio. org/faceq/. Accessed on 3 February 2019.
East C, Badia L, Marsh D, Pusic A, Klassen AF. Measuring Patient-Reported Outcomes in Rhinoplasty Using the FACE-Q: A Single Site Study. Facial Plast Surg. 2017;33(5):461-9.
Souza D, Ludtke C, Souza ERM, Scandura KMP, Weber MB. Periorbital hyperchromia. Surg Cosmet Dermatol. 2011;3(3):233-9.
Masuda Y, Takahashi M, Satou A. Dermatological Study on Dark Eye Circles and Their Treatment with Newly Developed Cosmetics. J Soc Cosmet Chem Japan. 2004;38(3):202-10.
Roh MR, Chung KY. Infraorbital dark circles: definition, causes, and treatment options. Dermatol Surg. 2009;35(8):1163-71.
Watanabe S, Nakai K, Ohnishi T. Condition known as “dark rings under the eyes” in the Japanese population is a kind of dermal melanocytosis which can be successfully treated by Q-switched ruby laser. Dermatol Surg. 2006;32(6):785-9.
Kikuchi K, Masuda Y, Hirao T. Imaging of hemoglobin oxygen saturation ratio in the face by spectral camera and its application to evaluate dark circles. Skin Res Technol. 2013;19(4):499-507.
Marx RE. Platelet-rich plasma: evidence to support its use. J Oral Maxillofac Surg. 2004;62(4):489-96.
Cho JW, Kim SA, Lee KS. Platelet-rich plasma induces increased expression of G1 cell cycle regulators, type I collagen, and matrix metalloproteinase-1 in human skin fibroblasts. Int J Mol Med. 2012;29(1):32-6.
Kim DS, Park SH, Park KC. Transforming growth factor-beta1 decreases melanin synthesis via delayed extracellular signal-regulated kinase activation. Int J Biochem Cell Biol. 2004;36(8):1482-91.
Yun WJ, Bang SH, Min KH, Kim SW, Lee MW, Chang SE. Epidermal growth factor and epidermal growth factor signaling attenuate laser-induced melanogenesis. Dermatol Surg. 2013;39(12):1903-11.
Cayırlı M, Calışkan E, Açıkgöz G, Erbil AH, Ertürk G. Regression of melasma with platelet-rich plasma treatment. Ann Dermatol. 2014;26(3):401-2.
Al-Saedy SJ, Al-Hilo MM, Al-Shami SH. Treatment of acne scars using fractional Erbium: YAG laser. Am J Dermatol Venereol. 2014;3(2):43-9.